CTx1000 / Celosia Therapeutics - LARVOL DELTA

Celosia Therapeutics…announced dosing of the first participant in its Phase 1b KOANEWA trial evaluating CTx1000, an investigational genetic medicine targeting pathological forms of the TDP-43 protein in people with amyotrophic lateral sclerosis (ALS)… (PRNewswire) - "The study is being conducted at the Neurology Department of Macquarie University Hospital in Sydney, Australia....KOANEWA is a first-in-human, open-label Phase 1b clinical trial, designed to evaluate the safety and tolerability of a single administration of CTx1000 in participants with ALS."

Trial status • Amyotrophic Lateral Sclerosis